Research progress of circulatory truncated B-type natriuretic peptides
10.3760/cma.j.cn114452-20230922-00159
- VernacularTitle:B型利钠肽不同循环截短形式的研究进展
- Author:
Qiao WANG
1
;
Peng XIAO
;
Li′na FENG
;
Jingyi REN
Author Information
1. 北京中医药大学研究生院，北京 100029
- Keywords:
Heart failure;
B-type natriuretic peptide;
Truncated forms;
Mass spectrometry
- From:
Chinese Journal of Laboratory Medicine
2024;47(3):323-331
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and mortality rate of heart failure (HF) are increasing annually, resulting in a huge medical and economic burden worldwide. B-type natriuretic peptide (BNP) is the gold standard biomarker of HF recommended by national and international guidelines for the diagnosis and prognosis evaluation of HF. Recent studies suggest that BNP can be truncated in multiple forms by different enzymes rather than complete fragments in circulation, which can be contributing to the diagnosis and classification of HF. The immunoassay mostly used in clinics are unable to distinguish different truncated BNP forms due to cross-reactivity of antibody, while mass spectrometry is more accurate because it can easily distinguish through their mass-to-charge ratios. With the maturation of ambient ionization mass spectrometry and ion mobility mass spectrometry, it can help to simplify sample pre-treatment and improve the separation efficiency, in order to explore the clinical value of the heterogeneity of BNP truncated forms.
